Letter to the Editor

Successful long-term prophylaxis with human plasma-derived C1 inhibitor in planning and carrying out pregnancy

Dear Editor,

Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is a rare autosomal dominant disorder characterized by recurrent attacks of edema in different locations, which may be peripheral or affect internal tissues, as the gastrointestinal tract causing abdominal pain or the upper airways, producing life-threatening asphyxia. The physiopathology of the disease involves several vasoactive peptides, such as bradykinin, which increase endothelial permeability and vascular leakage. The C1 inhibitor (C1-INH) quantitative or qualitative deficiency is the characteristic biomarker of the disease.

The clinical manifestations reduce the physical and social functioning with a significant impact in the quality of life of patients. Frequent attack triggers are stress, trauma and infections. Direct and indirect costs of the disease have been estimated on 42 000 US$ a year per patient, but when attack severity and frequency are considered, costs rise up to 92 000 US$. Therapy is addressed by treating or preventing acute attacks and the regimen should always be individualized. Blocking bradykinin receptor agents, kallikrein synthesis inhibitors and C1-INH are used as treatment for acute attacks. Human plasma-derived C1-INH (pdC1-INH) is used as treatment for acute attacks and can also be prophylactically administrated either before surgery and invasive procedures or continuously for long-term prophylaxis, when symptoms are frequent and/or severe. Treatment with attenuated androgens for long term prophylaxis has declined lately due to side effects.

During pregnancy, C1-INH-HAE can worsen due to the increased estrogen levels, although most series describe an unpredictable course. Even in the same woman, different pregnancies show differences in frequency and severity of angioedema (AE) attacks. Treatment options during pregnancy are limited. The administration of pdC1-INH has been proven safe and effective in acute attacks, but also as short and long-term prophylaxis. Fresh frozen plasma can be an alternative for acute attacks, it is cost-effective and safe, as viral transmission is minimal due to effective screening of blood products. However, its content of complement factors has the potential to worsen HAE symptoms. Antifibrinolytic agents such as tranexamic and epsilon aminocaproic acids can be used as prophylaxis; however, potential risks and benefits must be considered, and there are few data on their use during pregnancy. Attenuated androgens such as danazol, are contraindicated during pregnancy, in fact they should be withdrawn at least one month prior to pregnancy. There is no data about the use during pregnancy of the more recent treatments for C1-INH-HAE such as icatibant acetate, ecallantide or recombiant human C1-INH.

A 34 year-old woman with type 1 C1-INH-HAE was referred in March 2013 to get support to plan and carry out a second pregnancy. From diagnosis, in 2003, she was treated prophylactically with danazol 200 mg/day, presenting periods of amenorrhea as a side effect of the therapy. In December 2010, she discontinued danazol in order to plan her first pregnancy, which occurred in July 2011 (Table 1). From the first weeks after discontinuing danazol, AE attacks increased in frequency and severity, being almost continuous, requiring repeated on-demand administrations of pdC1-INH (Berinert®, 500–1000 IU). The uncountable attacks, forced her to a prolonged absenteeism from her work. Delivery occurred through the vaginal route without complications, under short-term prophylaxis with Berinert® (1000 IU). She returned to long-term prophylaxis with danazol immediately after delivery however, HAE attacks increased due to psychological stress and common respiratory and urinary infections, presenting frequent combined peripheral and abdominal attacks about twice a month and 2 laryngeal attacks, in June and December 2012, both treated with intravenous pdC1-INH.

Blood tests showed low levels of C4 (11 mg/dL) and C1-INH (9 mg/dL) with a functional C1-INH <10%. Blood cell counts, liver function tests and cholesterol were within normal range. Long-term prophylaxis with plasma-derived nanofiltered C1-esterase inhibitor (pdnfC1-INH), Cinryze®, was started in May 2013 and the patient was trained on intravenous self-administration of 1000 IU twice a week. Shortly after initiation of therapy, she referred important clinical improvement, being practically free of symptoms and danazol was promptly discontinued (Table 1).

The second pregnancy occurred in July 2014. She continued self-administered long-term prophylaxis with pdnfC1-INH with few mild peripheral attacks and a better performance at work. Delivery occurred through vaginal route without complications under prophylaxis with an extra dose of pdnfC1-INH (1000 IU) administered when the labor process started, immediately after arrival into the hospital. She chose not to breastfeed and continued on self-administration of 1000 IU every 4 days of pdnfC1-INH until now, with adequate control of the disease. Peripheral and abdominal attacks recurred 1–2 weeks after any attempt to reduce the dose or frequency of the prophylaxis.

We present the case of a woman with difficulties in getting pregnant due to the side effects of long-term prophylaxis with attenuated androgens for C1-INH-HAE. After starting long-term

http://dx.doi.org/10.1016/j.alit.2017.05.008
1323-8930/© 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1-INH was found to be the safest option as acute treatment, short-term prophylaxis, and long-term prophylaxis during pregnancy. In the reported case, self-administration continued throughout pregnancy without complications. As reported, patients with C1-INH-HAE have lower scores, both for physical and mental functioning, which directly affects work productivity. In this case, during the first pregnancy the prolonged sick leave increased the indirect costs of the disease.

Long-term prophylaxis with pdnFC1-INH seems to be a good alternative to accomplish and carry out pregnancy in women with C1-INH-HAE at a reproductive age.

Conflict of interest
The authors have no conflict of interest to declare.

In the reported case, self-administration continued throughout pregnancy without complications.

As reported, patients with C1-INH-HAE have lower scores, both for physical and mental functioning, which directly affects work productivity. In this case, during the first pregnancy the prolonged sick leave increased the indirect costs of the disease.

Long-term prophylaxis with pdnFC1-INH seems to be a good alternative to accomplish and carry out pregnancy in women with C1-INH-HAE at a reproductive age.

**Conflict of interest**

The authors have no conflict of interest to declare.

Susana Calaforra-Méndez a, Ethel Ibáñez Echevarría a, Carolina Perales Chordá a, María Verónica Pacheco-Coronel a, Agustín Fernández Lópezb, Dolores Hernández Fernández de Rojas a,*

* Corresponding author. Department of Allergy, Hospital Universitari i Politecnic La Fe, Valencia, Spain.

**References**


